Johnson & Johnson plans to invest more than $1 billion in a next-generation manufacturing facility that will produce advanced cell therapy technologies. The facility will be located in Lower Gwynedd Township, Pennsylvania.

Johnson & Johnson said the move will expand its U.S. manufacturing capacity along with its pipeline of transformational medicines for cancer, immune-mediated and neurological diseases. The facility will feature cutting-edge manufacturing processes and, once fully operational, will support over 500 biomanufacturing jobs, as well as over 4,000 construction jobs.

“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” said Johnson & Johnson CEO Joaquin Duato. The $1 billion investment in the new cell therapy manufacturing facility comes as part of the company’s previously announced plan to invest $55 billion in manufacturing, research and development, and technology in the U.S. through early 2029.